Common Specifications for Class D In Vitro Diagnostic Medical Devices
On 5 of July of 2022, the European Commission published the implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746.
Picture of Guilherme Semedo

Guilherme Semedo

Linkedin Instagram Facebook Address-card

For certain class D in vitro diagnostic medical devices, there are no harmonised standards to respond to some requirements of Annex I of Regulation (EU) 2017/746. However, there is a need to address public health concerns as they can pose significant risks for public health and patient safety. Therefore, it is appropriate to adopt common specifications for those devices in respect of those requirements.

The common technical specifications under the Directive 98/79/EC were set out in Commission Decision 2002/364/EC. Once the Regulation (EU) 2017/746 replaced the Directive 98/79/EC, some of those common technical specifications have to be updated to reflect the current state of the art.

Entry into force and date of application

Regulation (EU) 2022/1107:

  • Enters into force in 25 July 2022
  • Applies from 25 July 2024

Transitional provisions

To ensure a continuous high level of safety and performance of devices, as a transitional measure, it is presumed that devices in conformity with Decision 2002/364/EC are in conformity with the requirements for certain performance characteristics set out in Annex I of Regulation (EU) 2017/746 until 25 July 2024.

Devices that are not in conformity with the common technical specifications set out in Decision 2002/364/EC should adopt solutions to ensure an equivalent level of safety and performance.

Devices that are in conformity with the common specifications set out in Regulation (EU) 2022/1107 are presumed to be in conformity with the performance requirements referred in Annex I to Regulation (EU) 2017/746.

Which requirements of Annex I of Regulation (EU) 2017/746 are covered by the common specifications?

Regulation (EU) 2022/1107 lays down common specifications for certain class D in vitro diagnostic medical devices in respect to the following performance requirements set out in Annex I to Regulation (EU) 2017/746:

  • Section 9.1, points (a) and (b)
  • Section 9.3
  • Section 9.4, point (a)

List of annexes of Regulation (EU) 2022/1107

  • Annex I – general common specifications for devices covered by Annexes II to XIII
  • Annex II – common specifications for devices intended for detection of blood group antigens in the ABO, Rh, Kell, Duffy and Kidd blood group systems.
  • Annex III – common specifications for devices intended for detection or quantification of markers of human immunodeficiency virus (HIV) infection.
  • Annex IV – common specifications for devices intended for detection or quantification of markers of human T-cell lymphotropic virus (HTLV) infection.
  • Annex V – common specifications for devices intended for detection or quantification of markers of hepatitis C virus (HCV) infection.
  • Annex VI – common specifications for devices intended for detection or quantification of markers of hepatitis B virus (HBV) infection.
  • Annex VII – common specifications for devices intended for detection or quantification of markers of hepatitis D virus (HDV) infection.
  • Annex VIII – common specifications for devices intended for detection of markers of variant Creutzfeldt-Jakob disease (vCJD).
  • Annex IX – common specifications for devices intended for detection or quantification of markers of cytomegalovirus (CMV) infection.
  • Annex X – common specifications for devices intended for detection or quantification of markers of Epstein-Barr virus infection (EBV).
  • Annex XI – common specifications for devices intended for detection of markers of Treponema pallidum infection.
  • Annex XII – common specifications for devices intended for detection or quantification of markers of Trypanosoma cruzi infection.
  • Annex XIII – common specifications for devices intended for detection or quantification of markers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

further
reading
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
Guilherme Semedo February 24, 2023
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
Guilherme Semedo February 15, 2023
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
Guilherme Semedo February 13, 2023
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
Guilherme Semedo January 9, 2023
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
Guilherme Semedo December 13, 2022
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
Liliana Teles December 10, 2022
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
Filipa Ferreira October 11, 2022
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
Filipa Ferreira October 4, 2022

services

CONTACT US

  • info@criticalcatalyst.com
  • +351 91 200 43 51
    PT mobile network call
  • EUROPEAN UNION (HQ)
    679 Avenida da República
    4450-242 Matosinhos (PT)
  • UNITED KINGDOM
    49 Queen Victoria Street
    EC4N 4SA London (UK)